PMGC Holdings reported Q3 2024 financial results, with revenue of $527,478, down 4.9% year-over-year. Gross profit increased to $393,901, representing a 75% margin compared to 66% in Q3 2023. The company's net loss widened to $1,501,257 from $783,047 in the prior year quarter.Operating expenses rose 14.1% to $1,313,738, driven by higher consulting and professional fees. Research and development expenses increased slightly to $95,260. The company ended the quarter with $6,425,670 in cash, up from $3,326,851 at the end of 2023.PMGC Holdings recently acquired licenses for stem cell and probiotic technologies to expand its product pipeline. Management is focused on growing revenue, advancing clinical development, and pursuing strategic acquisitions to drive future growth. The company is also exploring potential spin-offs of subsidiaries to unlock shareholder value.

PMGC Holdings reported Q3 2024 financial results, with revenue of $527,478, down 4.9% year-over-year. Gross profit increased to $393,901, representing a 75% margin compared to 66% in Q3 2023. The company's net loss widened to $1,501,257 from $783,047 in the prior year quarter.Operating expenses rose 14.1% to $1,313,738, driven by higher consulting and professional fees. Research and development expenses increased slightly to $95,260. The company ended the quarter with $6,425,670 in cash, up from $3,326,851 at the end of 2023.PMGC Holdings recently acquired licenses for stem cell and probiotic technologies to expand its product pipeline. Management is focused on growing revenue, advancing clinical development, and pursuing strategic acquisitions to drive future growth. The company is also exploring potential spin-offs of subsidiaries to unlock shareholder value.